Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes immune-modulating therapies, anchored by ARCALYST — the first and only FDA-approved treatment for recurrent pericarditis — serving patients with inflammatory and autoimmune diseases.
- Company typePublic
- Founded2015
- HeadquartersHamilton, Bermuda
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kiniksa Pharmaceuticals does
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company founded in 2015 and headquartered in Bermuda (incorporated in the UK), listed on NASDAQ under ticker KNSA. The company develops and commercializes immune-modulating therapies targeting inflammatory and autoimmune diseases with high unmet need, with a strategic focus on cardiovascular indications. Its core product is ARCALYST (rilonacept), an IL-1α and IL-1β inhibitor that became the first and only FDA-approved therapy for recurrent pericarditis in March 2021, also approved for CAPS and DIRA. The clinical pipeline includes KPL-387 (Phase 2/3 IL-1 receptor antagonist mAb for recurrent pericarditis), Mavrilimumab (Phase 1 GM-CSFRα mAb for rare cardiovascular diseases), and KPL-404 (Phase 2 anti-CD40 mAb for rheumatoid arthritis), while vixarelimab is licensed globally to Roche and Genentech.
Kiniksa operates a specialty pharmaceutical commercial model, generating 100% of revenue from ARCALYST product sales through specialty pharmacy distribution channels and a field sales organization targeting specialist physicians including cardiologists and rheumatologists. The company had 4,550+ prescribing physicians and an estimated ~18% penetration of the addressable recurrent pericarditis patient population as of year-end 2025. ARCALYST delivered $677.6M in FY2025 revenue (62% YoY growth) and $214.3M in Q1 2026 (56% YoY growth), with 2026 guidance raised to $930-$945M. The company turned profitable in 2025 ($59M net income vs. $43.2M net loss in 2024), holds $468.1M in cash with no debt, and supports its franchise through the Kiniksa OneConnect patient services program, the RESONANCE Patient Registry, and disease-awareness initiatives including a DTC television campaign launched in April 2026.
The business is supported by a senior leadership team with deep rare-disease commercialization experience — most notably CEO Sanj K. Patel, who previously built and sold Synageva to Alexion for $9.7B in 2015. Geographic reach includes the US, UK, Switzerland, and Asia Pacific (via a Huadong Medicine partnership for ARCALYST and mavrilimumab, excluding Japan). The company is rated No. 1 in its industry group on the IBD Relative Strength Rating (93) as of 2026, with a market capitalization of approximately $3.59B.
Kiniksa Pharmaceuticals firmographics
Firmographics- Name
- Kiniksa Pharmaceuticals
- Legal name
- Kiniksa Pharmaceuticals International, plc
- Website
- https://kiniksa.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes immune-modulating therapies, anchored by ARCALYST — the first and only FDA-approved treatment for recurrent pericarditis — serving patients with inflammatory and autoimmune diseases.
- Ownership category
- akta.pro rank
Kiniksa Pharmaceuticals industry classification
Industry- Product category
- Specialty Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)
- akta.pro secondary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
Keywords
Where Kiniksa Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Hamilton
- HQ country
- Bermuda
Offices4 records
Markets served
Kiniksa Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- ARCALYST Product Sales: Commercial drug sales from ARCALYST (rilonacept), FDA-approved therapy for recurrent pericarditis, CAPS, and DIRA. Company generates 100% of revenue from this single drug.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | ARCALYST prescription drug pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
Kiniksa Pharmaceuticals product offering
Product offeringCore offering
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes immune-modulating therapies for inflammatory and autoimmune diseases. Its commercial product, ARCALYST (rilonacept), is an IL-1α and IL-1β inhibitor and the first and only FDA-approved therapy for recurrent pericarditis, also approved for CAPS and DIRA. The company also maintains a clinical-stage pipeline including KPL-387, mavrilimumab, KPL-404, and vixarelimab targeting serious diseases with unmet medical needs with a focus on cardiovascular indications.
Product overview
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with an FDA-approved therapy and clinical-stage pipeline targeting serious diseases with unmet medical needs, focused on cardiovascular indications. The core product is ARCALYST (rilonacept), an IL-1α and IL-1β inhibitor approved for recurrent pericarditis, CAPS, and DIRA. The pipeline includes KPL-387 (Phase 2/3 for recurrent pericarditis), Mavrilimumab (Phase 1 for rare cardiovascular diseases), KPL-404 (Phase 2 for rheumatoid arthritis), and Vixarelimab (Roche/Genentech global rights). Patient support is provided through Kiniksa OneConnect program, and research efforts are supported by the RESONANCE patient registry.
Differentiator
Problem solved
Functional benefit
Brands
- ARCALYST: FDA-approved therapy for recurrent pericarditis, CAPS, and DIRA. IL-1α and IL-1β inhibitor.
- Kiniksa OneConnect
Products and services
- ARCALYST (rilonacept) FDA-approved IL-1α and IL-1β inhibitor for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), and deficiency of interleukin-1 receptor antagonist (DIRA). The therapy addresses inflammatory conditions through IL-1 pathway inhibition, representing the first and only FDA-approved therapy for recurrent pericarditis in adults and pediatric patients 12 years and older.
- KPL-387 Investigational monoclonal antibody IL-1 receptor antagonist in liquid formulation with once-monthly subcutaneous dosing target profile for recurrent pericarditis treatment. Currently in Phase 2/3 clinical development (KPL-387-C211 trial). Efficacy and safety have not been evaluated by any regulatory authority.
- Mavrilimumab GM-CSFRα targeting agent in Phase 1 development evaluating rare cardiovascular diseases. Kiniksa holds worldwide rights excluding Middle East and North Africa.
- KPL-404 (Abiprubart) Anti-CD40 monoclonal antibody in Phase 2 development for rheumatoid arthritis. Worldwide rights held by Kiniksa.
- Vixarelimab OSMRβ targeting antibody previously licensed through global license agreement. Global rights held by Roche and Genentech for all indications; Kiniksa no longer commercializes this asset.
- Kiniksa OneConnect Patient support program providing personalized one-on-one support throughout the treatment journey, including financial assistance options for patients with recurrent pericarditis, CAPS, and DIRA.
- RESONANCE Patient Registry Voluntary patient-powered registry and network of physicians and researchers dedicated to advancing research efforts in recurrent pericarditis.
Quantifiable outcome
- 56% year-over-year revenue growth in Q1 2026
- +3 more outcomes
Companies that use Kiniksa Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles2 records
Kiniksa Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Kiniksa Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered global and regional.
- Roche and GenentechglobalGlobal license agreement with Roche and Genentech for rights to develop and commercialize vixarelinmab. Roche and Genentech hold global rights for all indications.
- Huadong MedicineregionalStrategic collaboration to develop and commercialize ARCALYST (rilonacept) and mavrilimumab in the Asia Pacific Region, excluding Japan. Huadong Medicine holds exclusive rights in this territory.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
Kiniksa Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- BioMarin Pharmaceutical: BioMarin is a larger rare-disease specialty biopharma with multiple Orphan Drug therapies. While broader than Kiniksa, BioMarin represents a relevant comparable for specialty pharma commercial scaling and pipeline diversification.
- Regeneron Pharmaceuticals: Regeneron is the original developer of rilonacept (ARCALYST) and licenses the trademark to Kiniksa. It is a broad incumbent in IL-1/inflammation biologics with Dupixent and other franchises, providing both competitive overlap and a strategic relationship with Kiniksa.
- Vertex Pharmaceuticals: Vertex is a broad specialty biopharma with rare disease franchises (CF, sickle cell) and a track record of converting rare disease leadership into a multi-billion-dollar franchise, providing a relevant comparable for Kiniksa's longer-term scaling potential.
Emerging players
- Apellis Pharmaceuticals: Apellis commercializes rare autoimmune ophthalmology therapies (Empaveli, Syfovre) using specialty pharmacy channels and rare-disease commercial infrastructure, with a similar growth profile and prescriber specialization.
- ChemoCentryx: ChemoCentryx (acquired by Amgen in 2022) was a rare autoimmune biopharma with Taveglin for ANCA-associated vasculitis, sharing Kiniksa's IL-pathway inflammation focus and orphan/specialty commercial approach.
Direct peers
- Corcept Therapeutics: Corcept is a specialty biopharma built around a single commercialized therapy (Korlym) with a focused sales force targeting specialist physicians, mirroring Kiniksa's orphan/specialty model and revenue trajectory.
- Madrigal Pharmaceuticals: Madrigal is a commercial-stage specialty biopharma that recently launched Rezdiffra, with comparable growth acceleration and specialty physician targeting. Both companies share a similar inflection from clinical-stage to commercial specialty pharma.
- Swedish Orphan Biovitrum (Sobi): Sobi markets Kineret (anakinra), an IL-1 receptor antagonist, and is a major rare-disease specialty biopharma. Sobi competes directly in IL-1 biology for inflammatory conditions and shares Kiniksa's orphan/specialty commercial model.
- Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease commercial biopharma with multiple Orphan Drug-designated therapies and a focus on genetically defined conditions, comparable to Kiniksa's orphan/specialty strategy and pipeline depth.
- Travere Therapeutics: Travere is a rare-disease specialty biopharma with commercial products and pipeline assets in nephrology and rare metabolic conditions, comparable in patient population targeting, regulatory strategy (Orphan Drug), and commercial-stage evolution.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Kiniksa Pharmaceuticals social profiles
Digital presenceKiniksa Pharmaceuticals compliance and trust
Trust signalCompliance5 records
Kiniksa Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kiniksa Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles10 records
Kiniksa Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kiniksa Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kiniksa Pharmaceuticals
What does Kiniksa Pharmaceuticals do?
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes immune-modulating therapies for inflammatory and autoimmune diseases. Its commercial product, ARCALYST (rilonacept), is an IL-1α and IL-1β inhibitor and the first and only FDA-approved therapy for recurrent pericarditis, also approved for CAPS and DIRA. The company also maintains a clinical-stage pipeline including KPL-387, mavrilimumab, KPL-404, and vixarelimab targeting serious diseases with unmet medical needs with a focus on cardiovascular indications.
Is Kiniksa Pharmaceuticals a public or private company?
Kiniksa Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Kiniksa Pharmaceuticals founded?
Kiniksa Pharmaceuticals was founded in 2015. It employs 251 to 500 people.
Where is Kiniksa Pharmaceuticals based?
Kiniksa Pharmaceuticals is headquartered in Hamilton, Bermuda.
How does Kiniksa Pharmaceuticals make money?
One revenue line is on record: ARCALYST Product Sales.
Who are Kiniksa Pharmaceuticals's main competitors?
Broad incumbents on record are BioMarin Pharmaceutical, Regeneron Pharmaceuticals and Vertex Pharmaceuticals. Emerging players are Apellis Pharmaceuticals and ChemoCentryx. Direct peers are Corcept Therapeutics, Madrigal Pharmaceuticals, Swedish Orphan Biovitrum (Sobi), Ultragenyx Pharmaceutical and Travere Therapeutics.
Does Kiniksa Pharmaceuticals have an API?
No public API is recorded for Kiniksa Pharmaceuticals.
What industry is Kiniksa Pharmaceuticals in?
Kiniksa Pharmaceuticals's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies, with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.